Identify Patients

In asymptomatic or minimally symptomatic mCRPC patients, treat them early with PROVENGE Immunotherapy

6 month duration

Treat early

  • To stimulate your mCRPC patients’ immune systems while they have a lower tumor burden1

Treat confidently

  • The NCCN recommends PROVENGE as first-line treatment for asymptomatic or minimally symptomatic mCRPC2
  • Updated NCCN guidelines support the use of PROVENGE before enzalutamide, abiraterone, chemotherapy, and other treatments in asymptomatic or minimally symptomatic mCRPC patients who have progressed2
  • PROVENGE does not preclude the use of subsequent therapies3,4

*Radiographic evidence of disease progression or rising prostate-specific antigen (PSA).
ADT=androgen deprivation therapy; mCRPC=metastatic castrate resistant prostate cancer; NCCN=National Comprehensive Cancer Network.

Most CRPC patients fit in the PROVENGE window at the time of metastatic diagnosis

6 month duration

Treat early — make sure your patients take advantage of the PROVENGE window

Keep in mind that if your patient:

Candidate for Provenge

He is a candidate for PROVENGE3

*Radiographic evidence of disease progression or rising PSA.

Learn about Mike's Experience with PROVENGE

REFERENCES:

  1. Data on file. Dendreon Corporation.
  2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V1.2015. www.nccn.org. Accessed December 10, 2014.
  3. Provenge [prescribing information]. Seattle, WA: Dendreon Corporation; 2014.
  4. Cheever MA, Higano CS. PROVENGE (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520-3526.
  5. Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010;17(S2):S72-S79.
  6. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.